took up its work in June 2017, has submitted an interim report to the Bavarian Parliament
News Interim report of the victim research project submitted to the Bavarian Parliament
At its session in early February, the European Parliament decided to give top
Max-Planck-Gesellschaft Homepage Newsroom Research News European Policy European Parliament
Position of the President on partial agreements reached by the EU Parliament and
budget increases Position of the President on partial agreements reached by the EU Parliament
the number of federal laws requiring approval by the upper house of the federal parliament
the number of federal laws requiring approval by the upper house of the federal parliament
President’s position on the EU financial planning for the years 2021 to 2027 with recovery plan
The Max Planck Society congratulates the negotiating partners of the European Parliament
Teaming Excellence as social duty
Against the background of the negotiations between the EU Commission, the European Parliament
The battle for women’s rights in Brazil is entering a new round
land rights of indigenous Brazilians is a very complicated matter in the Brazilian parliament
The battle for women’s rights in Brazil is entering a new round
land rights of indigenous Brazilians is a very complicated matter in the Brazilian parliament
A new amendment to an existing higher education law in Hungary is putting Budapest’s Central European University under threat. In an open letter to Prime Minister Viktor Orbán, Martin Stratmann, President of the Max Planck Society, calls for a reconsideration of the legislation.
On April 4, 2017, the Hungarian Parliament adopted a controversial amendment to the
The currently available tuberculosis vaccine BCG is over 90 years old – and its effectiveness is declining. An increasing number of mycobacterial strains are emerging, against which the current vaccine provides no protection. Scientists at the Max Planck Institute for Infection Biology in Berlin have developed an improved vaccine that has being undergoing tests on humans in clinical trials since 2008. The results of the phase I trial show that the vaccine candidate fulfils safety requirements. Initial results of the phase Ib trial indicate that the vaccine candidate’s active principle is effective.
latest European Parliament gives top priority to tuberculosis research At its session
